# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

# SCHEDULE 13G

(Rule 13d-102)

# INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No.)

Zymeworks Inc.
(Name of Issuer)
Common Stock, par value \$0.00001 per share
(Title of Class of Securities)
98985W102
(CUSIP Number)
December 22, 2022
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
□ Rule 13d-1(b)
☑ D.J. 12 J 1/a\
⊠ Rule 13d-1(c)
$\square$ Rule 13d-1(d)
The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in
prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).

1	NAME OF REPOR	TING DEDSON	<u> </u>	
1	NAME OF KEI OK	TAIME OF REFORM FERDOR		
	Biotechnology Value Fund, L.P.			
2		ROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵	
			(b) □	
			` ,	
3	SEC USE ONLY			
	CITIZENICI IID OD	DI AGE OF ORGANIZATION		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION		
	Delaware			
NUMBER OF	5	SOLE VOTING POWER		
SHARES		SOLD TOTAL OF THE CONTRACT OF		
BENEFICIALLY		- 0 -		
OWNED BY	6	SHARED VOTING POWER		
EACH				
REPORTING		3,146,377		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
		- 0 -		
	8	SHARED DISPOSITIVE POWER		
	0	SHARED DISTOSTITVE TO WER		
		3,146,377		
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
1.0	3,146,377			
10	CHECK BOX IF T	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)		
11	I ERCEIVI OI CEI	iso is its isostilia bi inicolii inicolii ()		
	5.0%			
12	TYPE OF REPORT	ING PERSON		
	PN			

1	NAME OF REPOR	TING PERSON	
	BVF I GP LL	C	
2		ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠
			(b) 🗆
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF SHARES	5	SOLE VOTING POWER	
BENEFICIALLY		- 0 -	
OWNED BY EACH	6	SHARED VOTING POWER	
REPORTING		3,146,377	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		- 0 -	
	8	SHARED DISPOSITIVE POWER	
9	ACCDECATE AM	3,146,377 OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
10	3,146,377	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	П
10	CHECK BOX II' II	THE AUGREGATE AMOUNT IN ROW (3) EACLODES CERTAIN SHARES	
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
12	5.0% TYPE OF REPORT	TING PERSON	
	00		

1	NAME OF REPORT	TING DEDSON		
1	NAME OF REPOR	NAME OF REFORMING LEASON		
	Biotechnology Value Fund II, L.P.			
2		ROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵	
_		toricand Born in Members of in Groot	(b) □	
			(-)	
3	SEC USE ONLY			
4	CITIZENSHIP OR 1	PLACE OF ORGANIZATION		
	Dalamana			
NUMBER OF	Delaware 5	SOLE VOTING POWER		
SHARES		SOLE VOTINGTOWER		
BENEFICIALLY		- 0 -		
OWNED BY	6	SHARED VOTING POWER		
EACH				
REPORTING		2,370,712		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
	8	- 0 - SHARED DISPOSITIVE POWER		
	8	SHARED DISPOSITIVE POWER		
		2,370,712		
9	AGGREGATE AMO	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	2,370,712			
10	CHECK BOX IF TH	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
11	DEDCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)		
11	FERCENT OF CLA	33 REFRESENTED DT AMOUNT IN ROW (9)		
	3.8%			
12	TYPE OF REPORT	ING PERSON		
	PN			

	NAME OF BEROR	EDIC DEDCOM		
1	NAME OF REPOR	NAME OF REPORTING PERSON		
	DAE II CD I			
	BVF II GP L	-	<b>√</b> . ■	
2	CHECK THE APP	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠	
			(b) □	
	CECTICE ONLY			
3	SEC USE ONLY			
4	CITIZENCUID OD	PLACE OF ORGANIZATION		
4	CITIZENSHIF OR	FLACE OF ORGANIZATION		
	Delaware			
NUMBER OF	5	SOLE VOTING POWER		
SHARES		SOLE VOINGTOWER		
BENEFICIALLY		- 0 -		
OWNED BY	6	SHARED VOTING POWER		
EACH				
REPORTING		2,370,712		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
		- 0 -		
	8	SHARED DISPOSITIVE POWER		
		2 270 712		
	A CODECATE AM	2,370,712 OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
9	AGGKEGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	2,370,712			
10		HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	П	
10	CILLON BOX II 1	TETIOGREGITE THIOUTI IN NOW (7) ENCEODES CERTIFICIENCES	ū	
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)		
	3.8%			
12	TYPE OF REPORT	TING PERSON		
	00			

1	NAME OF REPOR	RTING PERSON	
	Biotechnolog	gy Value Trading Fund OS LP	
2		ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Cayman Isla	nds	
NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER - 0 -	
OWNED BY EACH REPORTING	6	SHARED VOTING POWER 267,526	
PERSON WITH	7	SOLE DISPOSITIVE POWER - 0 -	
	8	SHARED DISPOSITIVE POWER 267,526	
9	AGGREGATE AM 267,526	IOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
10		HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CL.  Less than 1%	ASS REPRESENTED BY AMOUNT IN ROW (9)	
12	TYPE OF REPOR'	ΓING PERSON	

1	NAME OF REPORT	TING PERSON	
	BVF Partners OS Ltd.		
2		OS LIU. COPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵
			(b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR I	PLACE OF ORGANIZATION	-
	Cayman Island		
NUMBER OF SHARES	5	SOLE VOTING POWER	
BENEFICIALLY		- 0 -	
OWNED BY	6	SHARED VOTING POWER	
EACH		0/7 50/	
REPORTING PERSON WITH	7	267,526 SOLE DISPOSITIVE POWER	
TERSON WITH	,	SOLE DISTOSITIVE TOWER	
		- 0 -	
	8	SHARED DISPOSITIVE POWER	
		267,526	
9	AGGREGATE AMO	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	267,526		
10		HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
	Less than 1%	nya penaavy	
12	TYPE OF REPORT	ING PERSON	
	СО		

1	NAME OF REPORT	TING PERSON		
1	NAME OF REFOR	THIND OF REPORTING LEADON		
	BVF GP Holdings LLC			
2		ROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵	
			(b) □	
3	SEC USE ONLY			
4	CITIZENSHIP OR	PLACE OF ORGANIZATION		
•	CITIZENSIIII OK	TENCE OF ORGANIZATION		
	Delaware			
NUMBER OF	5	SOLE VOTING POWER		
SHARES				
BENEFICIALLY OWNED BY	6	- 0 - SHARED VOTING POWER		
EACH	O	SHARED VOTING FOWER		
REPORTING		5,517,089		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
	0	- 0 -		
	8	SHARED DISPOSITIVE POWER		
		5,517,089		
9	AGGREGATE AMO	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
1.0	5,517,089			
10	CHECK BOX IF TH	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)		
	8.8%			
12	TYPE OF REPORT	ING PERSON		
	00			
	00			

1	NAME OF REPORT	TING PERSON		
	BVF Partners L.P.			
2	CHECK THE APPR	COPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠	
			(b) 🗆	
3	SEC USE ONLY			
3	SEC OSE ONE!			
4	CITIZENSHIP OR I	PLACE OF ORGANIZATION		
	Delaware			
NUMBER OF	Delawate 5	SOLE VOTING POWER		
SHARES		SOLE FORMOTOWER		
BENEFICIALLY		- 0 -		
OWNED BY	6	SHARED VOTING POWER		
EACH REPORTING		5,870,000		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
	,	5022 2151 50111 / 2 1 0 1/ 21C		
		- 0 -		
	8	SHARED DISPOSITIVE POWER		
		5,870,000		
9	AGGREGATE AMO	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	_	
10	5,870,000	TE A CORECUTE A MOUNTE BY DOWN (A) ENGLY UNES CERTAIN ON A DES		
10	CHECK BOX IF TH	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)		
12	9.3%	DIG DEDGOV		
12	TYPE OF REPORT	ING PERSUN		
	PN, IA			

1	NAME OF REPORT	TING PERSON		
1	NAME OF REFORM	TAIME OF REFORM FERDON		
	BVF Inc.			
2		OPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵	
			(b) □	
3	SEC USE ONLY			
4	CITIZENCIIID OD I	PLACE OF ORGANIZATION	-	
4	CITIZENSHIP OK	PLACE OF ORGANIZATION		
	Delaware			
NUMBER OF	5	SOLE VOTING POWER		
SHARES				
BENEFICIALLY	_	- 0 -		
OWNED BY	6	SHARED VOTING POWER		
EACH REPORTING		5,870,000		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
TERESOTT WITH	,	SOLE DISTOSITIVE TO WER		
		- 0 -		
	8	SHARED DISPOSITIVE POWER		
		- 0 000		
9	A CCDEC ATE AMO	5,870,000 DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
9	AGGREGATE AMO	JUNI BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	5,870,000			
10		IE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)		
	9.3%			
12	TYPE OF REPORT	ING PERSON		
1-				
	CO			

1	NAME OF REPO	NAME OF REPORTING PERSON		
	Mark N. Lampert			
2	CHECK THE API	PROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠	
			(b) □	
3	SEC USE ONLY			
4	CITIZENSHIP OF	R PLACE OF ORGANIZATION		
	United State	S		
NUMBER OF	5	SOLE VOTING POWER		
SHARES				
BENEFICIALLY		- 0 -		
OWNED BY	6	SHARED VOTING POWER		
EACH				
REPORTING		5,870,000		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
	·			
		- 0 -		
	8	SHARED DISPOSITIVE POWER		
		5,870,000		
9	AGGREGATE AN	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
-				
	5,870,000			
10		THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
11	PERCENT OF CI	ASS REPRESENTED BY AMOUNT IN ROW (9)		
		2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		
	9.3%			
12	TYPE OF REPOR	TING PERSON		
	IN			

#### Item 1(a). Name of Issuer:

Zymeworks Inc., a Delaware corporation (the "Issuer").

## Item 1(b). Address of Issuer's Principal Executive Offices:

108 Patriot Drive, Suite A Middletown, Delaware 19709

# Item 2(a). Name of Person Filing

Item 2(b). Address of Principal Business Office or, if None, Residence

## Item 2(c). Citizenship

Biotechnology Value Fund, L.P. ("BVF") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

BVF I GP LLC ("BVF GP") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

Biotechnology Value Fund II, L.P. ("BVF2") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

BVF II GP LLC ("BVF2 GP") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

Biotechnology Value Trading Fund OS LP ("Trading Fund OS") PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands Citizenship: Cayman Islands

BVF Partners OS Ltd. ("Partners OS") PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands Citizenship: Cayman Islands

BVF GP Holdings LLC ("BVF GPH") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware BVF Partners L.P. ("Partners") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

BVF Inc.

44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

Mark N. Lampert ("Mr. Lampert") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: United States

Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."

## Item 2(d). Title of Class of Securities:

Common Stock, par value \$0.00001 per share (the "Shares").

## Item 2(e). CUSIP Number:

98985W102

# Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

	/x/	Not applicable.
(a)	//	Broker or dealer registered under Section 15 of the Exchange Act.
(b)	//	Bank as defined in Section 3(a)(6) of the Exchange Act.
(c)	//	Insurance company as defined in Section 3(a)(19) of the Exchange Act.
(d)	//	Investment company registered under Section 8 of the Investment Company Act.
(e)	//	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
(f)	//	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
(g)	//	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
(h)	//	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
(i)	//	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
(j)	//	A non-U.S. institution, in accordance with Rule 13d-1(b)(1)(ii)(J).
(k)	//	Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:

#### Item 4. Ownership

#### (a) Amount beneficially owned:

As of the close of business on January 3, 2023, (i) BVF beneficially owned 3,146,377 Shares, (ii) BVF2 beneficially owned 2,370,712 Shares and (iii) Trading Fund OS beneficially owned 267,526 Shares.

BVF GP, as the general partner of BVF, may be deemed to beneficially own the 3,146,377 Shares beneficially owned by BVF.

BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 2,370,712 Shares beneficially owned by BVF2.

Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 267,526 Shares beneficially owned by Trading Fund OS.

BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 5,517,089 Shares beneficially owned in the aggregate by BVF and BVF2.

Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 5,870,000 Shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS, and held in a certain Partners managed account (the "Partners Managed Account"), including 85,385 Shares held in the Partners Managed Account.

BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 5,870,000 Shares beneficially owned by Partners.

Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 5,870,000 Shares beneficially owned by BVF Inc.

The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

#### (b) Percent of class:

The following percentages are based on 63,003,370 Shares outstanding as of November 15, 2022, which is the total number of Shares outstanding as reported in the Issuer's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on November 25, 2022.

As of the close of business on January 3, 2023, (i) BVF beneficially owned approximately 5.0% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 3.8% of the outstanding Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 5.0% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 3.8% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 8.8% of the outstanding Shares, and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 9.3% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account).

- (c) Number of shares as to which such person has:
- (i) Sole power to vote or to direct the vote

See Cover Pages Items 5-9.

(ii) Shared power to vote or to direct the vote

See Cover Pages Items 5-9.

(iii) Sole power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

(iv) Shared power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

## Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

#### Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account.

Item 7. Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

See Exhibit 99.1.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certifications.

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

#### **SIGNATURE**

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: January 3, 2023

BIOTECHNOLOGY VALUE FUND, L.P.

By: BVF I GP LLC., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert Chief Executive Officer

BVF I GP LLC

By: /s/ Mark N. Lampert

Mark N. Lampert

Chief Executive Officer

BIOTECHNOLOGY VALUE FUND II, L.P.

By: BVF II GP LLC, its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

Chief Executive Officer

BVF II GP LLC

By: /s/ Mark N. Lampert

Mark N. Lampert

Chief Executive Officer

BVF PARTNERS OS LTD.

By: BVF Partners L.P., its sole member

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

BIOTECHNOLOGY VALUE TRADING FUND OS LP

By: BVF Partners L.P., its investment manager

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

BVF GP HOLDINGS LLC

By: /s/ Mark N. Lampert

Mark N. Lampert

Chief Executive Officer

BVF PARTNERS L.P.

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

BVF INC.

By: /s/ Mark N. Lampert

Mark N. Lampert

President

/s/ Mark N. Lampert

MARK N. LAMPERT

17

#### **Joint Filing Agreement**

The undersigned hereby agree that the Statement on Schedule 13G dated January 3, 2023 with respect to the Common Stock, par value \$0.00001 per share, of Zymeworks Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

Dated: January 3, 2023 BIOTECHNOLOGY VALUE FUND, L.P. BIOTECHNOLOGY VALUE TRADING FUND OS LP By: BVF I GP LLC., its general partner By: BVF Partners L.P., its investment manager By: BVF Inc., its general partner By: /s/ Mark N. Lampert Mark N. Lampert /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert President BVF I GP LLC BVF GP HOLDINGS LLC By: /s/ Mark N. Lampert By: /s/ Mark N. Lampert Mark N. Lampert Chief Executive Officer Mark N. Lampert Chief Executive Officer BIOTECHNOLOGY VALUE FUND II, L.P. BVF PARTNERS L.P. By: BVF II GP LLC, its general partner By: BVF Inc., its general partner /s/ Mark N. Lampert Mark N. Lampert /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert President BVF II GP LLC BVF INC. By: /s/ Mark N. Lampert

BVF PARTNERS OS LTD.

Mark N. Lampert

Chief Executive Officer

By: BVF Partners L.P., its sole member
By: BVF Inc., its general partner

By: /s/ Mark N. Lampert
Mark N. Lampert
President

/s/ Mark N. Lampert
MARK N. LAMPERT

/s/ Mark N. Lampert

Mark N. Lampert President